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Abstract 
Background: Debate exists as to whether statin pretreatment confers an increased risk of 90-
day mortality and symptomatic intracranial haemorrhage (sICH) in acute ischaemic stroke 
(AIS) patients treated with intravenous thrombolysis (IVT). We assessed the effects of 
undifferentiated lipid-lowering pretreatment on outcomes and interaction with low-dose 
versus standard-dose alteplase in a post hoc subgroup analysis of ENCHANTED (Enhanced 
Control of Hypertension and Thrombolysis Stroke Study). 
Methods: 3284 thrombolysis-eligible AIS patients (mean age 66.6 years; 38% women), with 
information on lipid-lowering pretreatment, were randomly assigned to low-dose (0.6mg/kg) 
or standard-dose (0.9mg/kg) intravenous alteplase within 4.5 hours of symptom onset. 615 
(19%) patients received statin or other lipid-lowering pretreatment. The primary clinical 
outcome was combined endpoint of death or disability (modified Rankin Scale (mRS) scores 
2-6) at 90 days. 
Results:  Compared with patients with no lipid-lowering pretreatment, those with lipid-
lowering pretreatment were significantly older, more likely to be non-Asian and more likely 
to have a medical history including vascular co-morbidity. After propensity analysis 
assessment and adjustment for important baseline variables at the time of randomisation, as 
well as imbalances in management during the first seven days of hospital admission, there 
were no significant differences in mortality (odds ratio (OR), 0.85; 95% confidence intervals 
(CI) 0.58-1.25, P=0.42), or in overall 90-day death and disability (OR 0.85, 95%CI 0.67-1.09, 
P=0.19), despite a significant decrease in sICH among those with lipid lowering pretreatment 
according to the ECASS-2 definition (OR 0.49, 95%CI 0.28-0.83, P=0.009). No differences 
in key efficacy or safety outcomes were seen in patients with and without lipid-lowering 
pretreatment between low- and standard-dose alteplase arms. 
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Conclusions:  Lipid-lowering pretreatment is not associated with adverse outcome in AIS 
patients treated with intravenous alteplase, whether assessed by 90-day death and disability or 
death alone. 
Clinical Trial Registration: Clinical Trial Registration-URL: http://www.clinicaltrials.gov. 
Unique identifier: NCT01422616 
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Introduction 
Intravenous alteplase (recombinant tissue plasminogen activator [rt-PA]) is the only approved 
medical reperfusion treatment in patients with acute ischaemic stroke (AIS); the earlier the 
treatment is given, the greater the proportional benefit [1]. Concerns over the risk of 
symptomatic intracerebral haemorrhage (sICH) with intravenous alteplase has led to lower 
doses being used in many AIS patient groups, particularly Asians [2] after a dose of 0.6 
mg/kg was approved for use in Japan.  The ENhanced Control of Hypertension ANd 
Thrombolysis strokE stuDy (ENCHANTED) was designed to evaluate the effectiveness of 
low-dose (0.6mg/kg body weight) compared to a standard-dose (0.9mg/kg) of intravenous 
alteplase in patients with AIS who fulfil guideline-recommended criteria for thrombolysis 
treatment [3]. Whilst the ENCHANTED trial failed to meet its primary non-inferiority 
outcome of 90-day death and disability defined by scores of 2 to 6 on the modified Rankin 
scale (mRS), low-dose alteplase was non-inferior on the key secondary efficacy outcome of 
the ordinal analysis of mRS scores [3]. 
Statins are recommended for both primary and secondary stroke prevention in patients at risk 
of ischaemic stroke. The 2013 American Heart Association (AHA) guidelines advise 
continuation of statin treatment post AIS in those pre-treated with statins based on 
observational data suggesting improved functional outcomes in AIS patients with statin 
pretreatment [4]. However, there is significant debate and uncertainty as to the association of 
lipid-lowering pretreatment with both sICH and functional outcome with intravenous 
thrombolysis [5].  Herein, we report the effects of lipid-lowering pretreatment on functional 
outcome and sICH in a post-hoc secondary analysis of the ENCHANTED trial. 
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Methods 
Patients 
The ENCHANTED trial is an international, multi-centre, prospective, randomised, open-
label, blinded-endpoint trial which used a 2x2 quasi-factorial design to assess the 
effectiveness of low- versus standard-dose alteplase in the completed arm, and more 
intensive- versus guideline-recommended control of blood pressure (BP) in the ongoing arm; 
full details of which are outlined elsewhere [3, 6]. Patients with a clinical diagnosis of AIS 
confirmed on brain imaging and fulfilling local criteria for thrombolysis treatment 
administered within 4.5 hours of symptom onset were randomly assigned to the dose-arm 
between 18 June 2012 and 14 October 2015. Randomised patients received low-dose 
(0.6mg/kg; 15% as bolus, 85% as infusion over 1 hour) or standard-dose (0.9mg/kg; 10% as 
bolus, 90% as infusion over 1 hour) intravenous alteplase.  The study protocol was approved 
by the appropriate ethics committee at each participating centre, and written informed consent 
was obtained from the patient or an appropriate surrogate.   
Procedures 
Key demographic and clinical characteristics were recorded at the time of enrollment, 
including whether patients were taking statin or other lipid-lowering treatment at hospital 
admission.  Stroke severity was measured using the National Institutes of Health stroke scale 
(NIHSS) at baseline, 24 hours, and at day 7 (or earlier, on discharge from hospital).  
Uncompressed digital images of all baseline and follow-up digital CT, MRI and angiogram 
images, were collected in DICOM format on a CD-ROM identified only with the patient’s 
unique study number, and analysed centrally for any intracranial haemorrhage by independent 
assessors blinded to clinical data, treatment, and date and sequence of scan.  Assessors graded 
any identified haemorrhage as intracerebral, using a range of standard definitions (see online 
supplement), and subarachnoid, intraventricular, subdural or other.   
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The primary clinical outcome was the combined endpoint of death or disability at 90 days, 
defined by scores of 2 to 6 on the mRS. The secondary (safety) outcome was sICH, defined 
according to several criteria from other studies (see online supplement).  
Statistical analysis 
Propensity score (PS) method was used to compare lipid pretreatment and no pretreatment 
groups given imbalances at baseline (Table 2). On the basis of coefficients from the 
multivariable logistic regression model, we generated a PS [7, 8] for each patient. Only 
patients with complete data were included in the analyses to maximize balancing of the PS 
analysis with the largest number of variables and to avoid the need to impute data. We used 
optimal matching 1:1 without replacement, with an initial caliper width-matching algorithm 
that equates to 0.12 (20% of the SD of the logit of the PS) [7]. Generalised estimating 
equations were used to test the effect of lipid-lowering pretreatment on primary and 
secondary outcomes, accounting for matching in the PS-matched sub-population [9].  
Logistic regression models were used to estimate associations for all the outcomes.  
Adjustments were made for the baseline covariates, and additionally for aspects of 
management over the first seven days following hospital admission.  In patients without lipid-
lowering pretreatment, the heterogeneity of alteplase treatment effects was tested by adding 
interaction terms to the statistical models. Two-sided P values are reported and P<0·05 was 
considered statistically significant.  The SAS version 9.3 (SAS Institute, Cary, NC) was used 
for the analysis. 
Role of the funding source 
The sponsors had no role in the study design, data collection, data analysis, data interpretation 
or writing of the report.  All authors had full access to the study data.  The corresponding 
author had final responsibility for the decision to submit the paper for publication.  
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Results 
These analyses included 3,284 patients (38% female) with information available on lipid-
lowering pretreatment. A total of 615 patients (19%) received statin or other lipid-lowering 
pretreatment at baseline, and were significantly older and more likely to have a medical 
history of other vascular co-morbidity, including hypertension, previous stroke, coronary 
artery disease, diabetes and hypercholesterolaemia, and associated medical therapy, including 
antihypertensive, aspirin or other antiplatelet, and glucose-lowering therapy, with concomitant 
premorbid mRS score of 1 (Table 1). Other baseline characteristics are shown in Table 1. 
Overall, patients with lipid-lowering pretreatment were heavier, and accordingly received 
significantly higher bolus and infusion alteplase doses, even though more patients were 
randomised to the low-dose arm of the trial in the lipid-lowering pretreatment group (see 
online supplement Table S1). In addition, patients with lipid-lowering pretreatment were 
significantly more likely to receive antithrombotic therapy in the first 24 hours following 
thrombolysis, and significantly more likely to be mobilised by a therapist, given 
rehabilitation, admitted to a stroke unit, and received subcutaneous heparin or neurosurgical 
intervention during the first seven days (see online supplement Table S1). Full details of 
management from randomisation over the first seven days are provided in the online 
supplement Table S1.  
After adjustment for important baseline variables at the time of randomisation, and for 
imbalances in management during the first seven days of hospital admission, there were no 
significant differences in key 90-day outcomes between those patients taking lipid-lowering 
therapy compared to those not taking lipid-lowering pretreatment: mRS of 2 to 6 (adjusted 
odds ratio (aOR): 0.85, 95% confidence intervals (CI) 0.67-1.09, p=0.19) or mRS of 3 to 6 
(aOR: 0.83, 95% CI 0.65-1.06, p=0.13) (Figure 1). In addition, there was no significant 
difference in 90-day mortality (aOR: 0.85, 95% CI 0.58-1.25, p=0.42) (Figure 1). Similarly, 
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no significant differences were seen in sICH rates between patients with and without lipid-
lowering pretreatment across a broad range of definitions except ECASS2, which was 
significantly lower for patients with lipid-lowering pretreatment (adjusted OR: 0.49, 95% CI 
0.28-0.83, p=0.009) (Table 3).  
Finally, there were no significant differences in the main efficacy (Figure 2 and online 
supplement Table S2) and safety (online supplement Table S3) outcomes between low-dose 
and standard-dose alteplase in patients with and without lipid-lowering pretreatment. 
Discussion 
This post-hoc subgroup secondary analysis of the ENCHANTED trial has shown that lipid-
lowering pretreatment is not associated with adverse outcome in AIS patients treated with 
intravenous alteplase, whether assessed by 90-day death and disability, death alone, or sICH. 
Furthermore, no significant differences were seen in key efficacy and safety outcomes by 
alteplase dose between patient groups with and without lipid-lowering pretreatment. 
Several studies have raised concerns about the risk of statin pretreatment and sICH following 
intravenous thrombolysis for AIS [10], though importantly without an impact on 90-day 
functional outcomes. However, other retrospective analyses have suggested that statin 
pretreatment, when continued during the acute phase, may improve both short- and long-term 
outcome [11, 12]. The most recent study concluded that statin pretreatment was independently 
associated with a higher odds of early clinical recovery (defined as reduction in baseline 
NIHSS score of ≥10 points) with no adverse outcomes in AIS patients treated with 
intravenous thrombolysis [12]. To date, the majority of these data arise from registry studies 
[13], and there is a lack of prospective studies to confirm safety concerns or indeed perceived 
benefits. Therefore, the large, prospective ENCHANTED trial with approximately 20% of 
patients receiving lipid-lowering pretreatment provides the largest randomised dataset to 
address these questions alongside a robust propensity analysis to assess baseline differences. 
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In keeping with previous studies, there was no significant difference in mortality or in 
adjusted overall 90-day death and disability [10, 12]. However, in agreement with some 
previous studies [10, 14], a significant difference was seen in sICH rates determined using 
ECASS2 criteria between patients with and without lipid-lowering pretreatment in favour of 
lipid-lowering pretreatment. Interestingly, the SITS-MOST and ECASS3 sICH criteria are 
also borderline significant for with and without lipid-lowering pretreatment.  SITS-MOST, 
ECASS2, and ECASS3 sICH criteria all relate to an increase of 4 NIHSS points, but NINDS 
sICH criteria are associated with any recorded deterioration in NIHSS and was non-
significant in this study.  Therefore, lipid lowering pretreatment might be associated with 
sICH with change in neurological status beyond a certain NIHSS threshold. However, overall 
the ECASS2 findings should be weighed against the majority of standard definitions for sICH 
assessed finding no significant association with lipid-lowering pretreatment.  
A key limitation of our study is that we recorded whether patients were on statin or other 
lipid-lowering therapy at baseline, but did not distinguish between these lipid-lowering 
therapies or the duration of treatment. However, it is likely that the majority of patients were 
treated with statins, and that the prescription had been chronic given the medical history of 
vascular co-morbidities. A further limitation of this study is the lack of serum LDL-C level 
measurement. It is possible that there were lower LDL-C levels at baseline in the non-lipid 
lowering group. Lower lipid levels are relevant as cohort and case-control studies have 
demonstrated lower serum lipid level and increased risk of ICH [15-17]. Lastly, other 
limitations include those related to an open-label trial, despite our efforts to minimise 
reporting bias, concealment of treatment allocation, rigorous assessment of adverse events, 
and blinded evaluation of clinical outcomes using established criteria.  As the ENCHANTED 
trial included patients with generally milder stroke severity with a slightly longer treatment 
delay from onset than in previous trials [1] or registries [18], there may be concerns over the 
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generalisability of these data, while imprecision in the estimates of the treatment effect may 
have arisen from the timing and inter-observer variability in scoring of the mRS [19]. 
Conclusions 
In conclusion, our study findings from the largest intravenous thrombolysis study to date 
provide further evidence that lipid-lowering pretreatment is not associated with adverse 
effects on 90-day death and disability. The potential benefits of statins on early clinical 
recovery in AIS patients treated with intravenous thrombolysis therapy requires further 
exploration. 
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Figure Legends 
 
Figure 1: Major clinical outcomes at 90 days by lipid-lowering pretreatment 
Footnote: This figure shows after adjustment for important baseline variables at the 
time of randomisation, and for imbalances in management during the first seven days 
of hospital admission, the differences in key 90-day outcomes between those patients 
taking lipid-lowering therapy compared to those not taking lipid-lowering 
pretreatment. 
 
Figure 2: Global functional outcome at 90 days in patients with and without 
lipid-lowering pretreatment by randomised treatment 
Footnote:  The figure shows the raw distribution of scores on the modified Rankin 
scale (mRS) at 90 days.  Scores on the mRS range from 0 to 6, with 0 indicating no 
symptoms, 1 symptoms without clinical significant disability, 2 slight disability, 3 
moderate disability, 4 moderately severe disability, 5 severe disability, and 6 death.  
Unadjusted odds ratios (and 95% confidence intervals) are provided for ordinal shift 
of mRS between low- and standard-dose intravenous alteplase by patients with and 
without lipid-lowering pretreatment. 
 
 
